Evidence Growing Metformin Safe in Many With Diabetes and CKD Evidence Growing Metformin Safe in Many With Diabetes and CKD

Rates of acidosis comparable in metformin-treated and nontreated patients with type 2 diabetes and mild to moderate chronic kidney disease when eGFR is at least 30 mL/min/1.73 m2.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Related Links:

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
CONCLUSIONS: Serum ALP level was positively and independently associated with baPWV in men and women, suggesting that an elevated ALP level may be a useful surrogate marker for arterial stiffness in adult men and women. PMID: 31092766 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - Category: Cardiology Tags: J Atheroscler Thromb Source Type: research
Publication date: Available online 14 May 2019Source: American Journal of Kidney DiseasesAuthor(s): Andrew S. Allegretti, Wenbin Zhang, Wenjiong Zhou, Tara K. Thurber, Scott P. Rigby, Cynthia Bowman-Stroud, Carlos Trescoli, Pierre Serusclat, Mason W. Freeman, Yuan-Di C. HalvorsenRationale &ObjectiveHyperglycemia exacerbates the progression of chronic kidney disease (CKD), but most glucose-lowering therapies do not address morbidities associated with CKD. Sodium/glucose cotransporter 2 (SGLT2) inhibitors offer potential benefits to patients with diabetes and CKD, but their effectiveness may be diminished with ...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Bardoxolone methyl attenuates inflammation by inducing Nrf2 and suppressing NF- κB. The Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes (BEACON) trial was a phase 3 placebo-controlled, randomized, double-blind, parallel-group, international, multicenter trial in 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney dis ease. BEACON was terminated because of safety concerns, largely related to a significant increase in early heart failure events in patients randomized to bardoxolone methyl.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Clinical Trial Source Type: research
ConclusionPreeclamptic women with risk factors for PPCM and women with pePPCM at increased risk of MACE should be followed closely. Further studies are required to determine whether preeclampsia affects the long-term prognosis of women with PPCM.
Source: Pregnancy Hypertension: An International Journal of Womens Cardiovascular Health - Category: OBGYN Source Type: research
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
RenalytixAI has won  Break Through Device designation from FDA for KidneyIntelX a technology that could help diagnose kidney disease. This is the first such designation for an AI-enabled diagnostic for kidney disease publicly announced by any company. KidneyIntelx was designed in an effort to curtail the estimated $114 billion annual cost of chronic and end-stage kidney disease to the U.S. healthcare system. “The technology is a combination of a multiplex lab-based test measuring three biomarkers (sTNFR1, sTNFR2 and KIM1) that are shown to be prognostic in nature for rapid progress...
Source: MDDI - Category: Medical Devices Authors: Tags: Digital Health Source Type: news
Hui-Min Liu1,2, Qin Hu3, Qiang Zhang4, Guan-Yue Su5, Hong-Mei Xiao1,2, Bo-Yang Li1,2, Wen-Di Shen1,2, Xiang Qiu1,2, Wan-Qiang Lv1,2 and Hong-Wen Deng1,2,6* 1Center of System Biology and Data Information, School of Basic Medical Science, Central South University, Changsha, China 2Center of Reproductive Health, School of Basic Medical Science, Central South University, Changsha, China 3Kangda College of Nanjing Medical University, Nanjing, China 4College of Public Health, Zhengzhou University, Zhengzhou, China 5Institute of Biomedical Engineering, West China School of Basic Medical Sciences and Forensic Medicine, ...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Dominique E. Martin1,2, Amanda K. Jones1,3, Sambhu M. Pillai1,4, Maria L. Hoffman1,5, Katelyn K. McFadden1,6, Steven A. Zinn1, Kristen E. Govoni1 and Sarah A. Reed1* 1Department of Animal Science, University of Connecticut, Storrs, CT, United States 2Department of Psychology, Providence College, Providence, RI, United States 3Department of Pediatrics, School of Medicine, University of Colorado, Aurora, Aurora, CO, United States 4School of Medicine, Georgetown University, Washington, DC, United States 5Department of Fisheries, Animal and Veterinary Sciences, The University of Rhode Island, Kingston, RI, United St...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Publication date: Available online 29 April 2019Source: The Lancet Diabetes &EndocrinologyAuthor(s): John M Dennis, Beverley M Shields, William E Henley, Angus G Jones, Andrew T HattersleySummaryBackgroundResearch using data-driven cluster analysis has proposed five subgroups of diabetes with differences in diabetes progression and risk of complications. We aimed to compare the clinical utility of this subgroup-based approach for predicting patient outcomes with an alternative strategy of developing models for each outcome using simple patient characteristics.MethodsWe identified five clusters in the ADOPT trial (n=435...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research
More News: Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Health | Metformin | Urology & Nephrology